MedTech Metro: Showcasing New York's Bio/Med Technology Companies

Sponsored by Epstein Becker & Green, P.C.

MedTech Metro is an intimate forum and networking series designed to showcase New York's bioscience/medical technology before an audience of investors, business leaders, and health care providers. This 2014 series will feature three companies seeking investment or partners and a keynote speaker at each event. MedTech is the hub of New York State's bioscience and medical technology industry. It is an active association of nearly 100 pharmaceutical, biotech, and medical technology companies, their suppliers and service providers and research universities.

Keynote:

President of Zimmons International Communications, Inc. — Jennifer K. Zimmons, Ph.D.
In this role, Dr. Zimmons manages all aspects of client services. Clients include private companies looking to develop/enhance their brand awareness, corporate messaging, and media recognition (industry/financial/advocacy) as well as public companies (domestic and international) requiring various types of investor, analyst, and media exposure within the United States.

Her keynote will discuss:

• Realism and good communication in capital raises
• Managing investor and company expectations
• Real-life experiences with family offices versus larger investment funds

Presenting Companies:

Raland Therapeutics Inc. — Bill Rader, President and CEO
Raland Therapeutics Inc. is a development stage company focused on biosensor systems for life sciences. Raland's proprietary technology is showcased in the CytoComm Living Biosensor System, a real time monitoring system for biological signaling and cellular responses in oncology and other applications. The system transmits live data through the cloud to Raland's data acquisition and analysis software. Using this system, real-time results are available to caregivers or researchers at their desk or in remote locations.

Raland is seeking $3-10 million in funding to support technology development.

Medical Acoustics — Frank Codella, President
The FDA-cleared Lung Flute is the only product that uses sound vibration to stimulate your body's natural mucus-clearing system - effectively thinning and dislodging mucus deep in the lungs so that it's easier to cough up. The small, reusable, plastic device is non-invasive, easy to use and drug-free - just blow into the mouthpiece and the device will do the rest. Clinical tests have proven the Lung Flute's ability to break up mucus in the lungs, making it equally effective for both therapeutic and diagnostic use. Unlike other devices, which rely on pressure and can't reach deep lung mucus, the Lung Flute's technology is based on low-frequency acoustic waves that are produced when you blow into the flute-shaped device.

Medical Acoustics is seeking new strategic partnerships to augment its distribution strategy. The Lung Flute is currently marketed within hospitals to respiratory departments and to home care agencies. The company is particularly focused on the need to improve home care management of COPD.

Immunovent, LLC — Kate Rochlin, PhD, Chief Science Officer
Immunovent, LLC is an allergy diagnostics company that has developed the Local Allergy Mucosal Brush (LAMB-Dx) test. LAMB-Dx is a specialized, sensitive assay that detects the small amounts of antigen-specific IgE from epithelial and mucosal cells in allergy-symptomatic tissues, such as the nose and mouth, which no other test can do. Clinical proof-of-concept data demonstrating the efficiency of this testing method has been published for both airborne and food allergies. LAMB-Dx will have particular utility as a companion diagnostic to antigen-specific immunotherapy, the only disease-modifying treatment modality for allergic disease. Moreover, the simple and patient-friendly LAMB-Dx method does not involve needles, making it ideal for the pediatric population.

Immunovent is now seeking $1-2 million to support development and launch of the initial LAMB-Dx by 2016. The company is also seeking strategic development partners who can offering this test to clinicians, such as clinical reference labs.

Agenda:

To register, please click here.

If you have questions about this briefing, please contact
Kiirsten Lederer at (212) 351-4668 or klederer@ebglaw.com.